News & Updates
Filter by Specialty:
High-flow oxygen does not reduce mortality in COVID-19 respiratory failure
The use of high-flow nasal cannula oxygen, as opposed to standard oxygen, in the first-line setting, did not reduce mortality rates in patients admitted to intensive care units (ICUs) for respiratory failure due to COVID-19, results of the SOHO-COVID trial showed.
High-flow oxygen does not reduce mortality in COVID-19 respiratory failure
20 Nov 2022CRT vs SBRT: Which approach yields better outcomes in PDAC?
Multiagent chemotherapy (MAC) followed by conventionally fractionated radiotherapy (CRT) shows rates of margin-negative resection (R0) and pathologic complete response similar to those of MAC plus stereotactic body radiotherapy (SBRT) in patients with localized pancreatic ductal adenocarcinoma (PDAC), according to a study. However, MAC plus CRT is associated with less regional lymphatic disease.
CRT vs SBRT: Which approach yields better outcomes in PDAC?
20 Nov 2022Low use of CVD prevention strategies in people with HIV
There is an underutilization of cardiovascular disease (CVD) prevention strategies in people living with HIV (PLHIV) who are at risk of CVD, according to a study presented at HIV Glasgow 2022.
Low use of CVD prevention strategies in people with HIV
18 Nov 2022Oral ritlecitinib shows promise against nonsegmental vitiligo
The use of ritlecitinib, an oral JAK3/TEC inhibitor, appears effective for the treatment of nonsegmental vitiligo (NSV) and is well-tolerated for over 48 weeks of follow-up, reports a recent study.
Oral ritlecitinib shows promise against nonsegmental vitiligo
17 Nov 2022Long-term relugolix combo helps with heavy periods, anaemia in women with uterine fibroids
Treatment with relugolix combination for up to 52 weeks yields sustained reductions in heavy menstrual bleeding as well as subsequent increases in iron stores in women with uterine leiomyomas, as shown in a study.
Long-term relugolix combo helps with heavy periods, anaemia in women with uterine fibroids
16 Nov 2022Adjunctive semaglutide yields additional weight loss in teens with obesity
Once-weekly treatment with semaglutide, when administered with lifestyle intervention, leads to greater reduction in body mass index among adolescents with obesity as compared with lifestyle intervention alone, as shown in the STEP TEENS study.